The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
Migraine
The reason for this 12-month, open-label study is to see if the study drug lasmiditan is safe and effective for the intermittent acute treatment of migraine in children aged 6 to 17. The study will last about 12 months and may include up to 7 visits.
A 12-Month Study of Lasmiditan (LY573144) Treatment in Children Aged 6 to 17 With Migraine
-
Central Research Associates, Birmingham, Alabama, United States, 35205
Rehabilitation & Neurological Services, Huntsville, Alabama, United States, 35805
Xenoscience, Phoenix, Arizona, United States, 85004
Phoenix Children's Hospital, Phoenix, Arizona, United States, 85016
Perseverance Research Center, Scottsdale, Arizona, United States, 85254
Center for Neurosciences, Tucson, Arizona, United States, 85718
Arkansas Children's, Little Rock, Arkansas, United States, 72202
Core Healthcare Group, Cerritos, California, United States, 90703-2751
Sun Valley Research Center, Imperial, California, United States, 92251
Miller Children's & Women's Hospital Long Beach, Long Beach, California, United States, 90806
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
6 Years to 17 Years
ALL
No
Eli Lilly and Company,
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM, STUDY_DIRECTOR, Eli Lilly and Company
2026-03-31